Fennec Pharmaceuticals Set for Positive Earnings Report on March 24
Fennec Pharmaceuticals (NASDAQ:FENC) is anticipated to report a profit of 4 cents per share in Q4, reversing last year's losses. Additionally, a recent settlement of patent litigation concerning PEDMARK may bolster investor confidence ahead of the earnings announcement.
View signal analysis